Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04286009 · ClinicalTrials.gov registry record
Pathogenesis and Mechanisms of Mitral Annular Calcification
A clinical trial of Mitral Annulus Calcification, sponsored by Mayo Clinic.
- Completed
- Registry status
- 45
- Enrollment target
- 1
- Study location
NCT04286009: Completed study of Mitral Annulus Calcification, sponsored by Mayo Clinic.
NCT04286009 is a study of Mitral Annulus Calcification that has completed, run by Mayo Clinic. The registered enrollment target is 45 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04286009, a study of Mitral Annulus Calcification, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
Researchers are testing blood or mitral valve tissue to better understand the reasons why Mitral Annular Calcification (MAC) develops in patients with heart disease.
Primary Outcome
Measured by Endothelial Progenitor Cells osteoblastic phenotype (EPC-OCNs) in Mitral Annular Calcification (MAC)
Conditions Studied
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2020-07-28 |
| Est. Completion | 2024-04-01 |
What the finished NCT04286009 record still lists
NCT04286009 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target.
The record links to 1 condition, with Mitral Annulus Calcification appearing as the primary indexed condition, and to 0 interventions.
NCT04286009 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT04286009 about?
NCT04286009 is a clinical study titled "Pathogenesis and Mechanisms of Mitral Annular Calcification". Researchers are testing blood or mitral valve tissue to better understand the reasons why Mitral Annular Calcification (MAC) develops in patients with heart disease.
What is the current status of trial NCT04286009?
This trial is currently completed. The enrollment target is 45 participants. The study started on 2020-07-28. Estimated completion is 2024-04-01.
What conditions does trial NCT04286009 study?
This clinical trial studies the following conditions: Mitral Annulus Calcification.
Who is sponsoring clinical trial NCT04286009?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04286009 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mitral Annulus Calcification
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI